Glycopolysialylation of blinatumomab
AssigneeLipoxen Technologies Limited
InventorsAnton Igonin, Dmitry Genkin, Curtis Lockshin
Life of this patent
Estimating the term…
Abstract
A composition comprising a population of polysaccharide-blinatumomab conjugates, wherein the polysaccharide is covalently linked to the blinatumomab. A method of increasing the efficacy of a therapeutic agent in the treatment of B-cell precursor acute lymphoblastic leukemia (ALL), wherein the therapeutic agent is a PSA-drug conjugate, wherein the conjugate comprises PSA covalently linked to blinatumomab, and wherein the PSA of the conjugate binds to DNA and histones of NET extracellular fibrils.
Claims18
A composition comprising a population of polysaccharide-blinatumomab conjugates, wherein the polysaccharide is covalently linked to the blinatumomab.
A composition comprising a population of polysaccharides and blinatumomab.
Dependencies are inferred from the claim text.